<p>Geode Capital Management LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第四季度将其在 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免费报告）中的持仓增加了 1,600.1%。该公司在本季度额外购买了 1,855,907 股后，持有该公司 1,971,894 股股票。根据其最近向证券交易委员会（SEC）提交的文件，Geode Capital Management LLC 拥有 Tonix Pharmaceuticals 约 105.45% 的股份，价值 650,000 美元。</p>
<p>获取 <strong>Tonix Pharmaceuticals</strong> 警报：</p>
<ul>
<li>制药狂潮：波动性点燃生物技术行业</li>
</ul>
<p>另外，Commonwealth Equity Services LLC 在第四季度购买了 Tonix Pharmaceuticals 的新股份，价值 40,000 美元。目前 82.26% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>TNXP 一直是多份研究报告的主题。Noble Financial 在 3 月 20 日的报告中重申了 &#34;跑赢大盘&#34; 的评级，并对 Tonix Pharmaceuticals 的股票设定了 70.00 美元的目标价。StockNews.com 于 2 月 10 日的研究报告中开始覆盖 Tonix Pharmaceuticals，并对该股票给予了 &#34;卖出&#34; 的评级。</p>
<ul>
<li>Tonix Pharmaceuticals 是下一个生物技术突破吗？</li>
</ul>
<p><strong>查看我们对 Tonix Pharmaceuticals 的最新分析</strong></p>
<h2>Tonix Pharmaceuticals 股价上涨 10.9%</h2>
<p>周一，TNXP 的股价开盘为 20.00 美元。Tonix Pharmaceuticals Holding Corp. 的 52 周低点为 6.76 美元，52 周高点为 672.00 美元。该公司的债务与股本比率为 0.07，速动比率为 2.81，流动比率为 3.33。该公司的 50 日移动平均线为 16.88 美元，200 日移动平均线为 20.69 美元。该股票的市值为 1.287 亿美元，市盈率为 0.00，贝塔值为 1.50。</p>
<p>Tonix Pharmaceuticals（NASDAQ:TNXP - 获取免费报告）最后一次公布财报是在 3 月 18 日，报告显示该季度每股收益（EPS）为（9.77）美元，低于市场共识预期的（6.23）美元，差额为（3.54）美元。该季度的营业收入为 258 万美元，而分析师的预期为 320 万美元。Tonix Pharmaceuticals 的净利润率为负 1,197.86%，股本回报率为负 163.95%。卖方分析师预计 Tonix Pharmaceuticals Holding Corp. 在当前财政年度的每股收益将为 -1762.5。</p>
<h2>Tonix Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Tonix Pharmaceuticals Holding Corp. 是一家生物制药公司，专注于开发、发现、商业化和许可治疗人类疾病和减轻痛苦的治疗药物。它市场销售 Zembrace SymTouch 和 Tosymra，用于治疗成人急性偏头痛（有或没有先兆）。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Tonix Pharmaceuticals</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>西部数据：存储行业是否准备反弹？</li>
<li>深入了解买卖差价</li>
<li>Wingstop 股票因第一季度业绩超预期和扩张前景而上涨</li>
<li>三只股票保护您的投资组合免受冠状病毒传播的影响</li>
<li>为什么像埃克森美孚和赫斯这样的能源股票重新受到关注</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>您现在应该投资 1,000 美元在 Tonix Pharmaceuticals 吗？</h2>
<p>在您考虑 Tonix Pharmaceuticals 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Tonix Pharmaceuticals 并不在名单上。</p>
<p>虽然 Tonix Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Tonix 医药控股

<p>Geode Capital Management LLC 在第四季度将其在 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) 的持股比例增加了 1,600.1%，收购了 1,855,907 股，使其总持股达到 1,971,894 股，价值 650,000 美元。机构投资者持有该股票的 82.26%。分析师对 TNXP 设定的目标价为 70.00 美元，而该股票开盘价为 20.00 美元，52 周的价格区间为 6.76 美元至 672.00 美元。该公司报告上个季度每股亏损 9.77 美元，未能达到预期，并预计本财年每股亏损将达到 -1762.5 美元</p>

<p>Geode Capital Management LLC grew its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) by 1,600.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,971,894 shares of the company's stock after purchasing an additional 1,855,907 shares during the quarter. Geode Capital Management LLC owned approximately 105.45% of Tonix Pharmaceuticals worth $650,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Geode Capital Management LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第四季度将其在 Tonix Pharmaceuticals Holding Corp.（NASDAQ:TNXP - 免费报告）中的持仓增加了 1,600.1%。该公司在本季度额外购买了 1,855,907 股后，持有该公司 1,971,894 股股票。根据其最近向证券交易委员会（SEC）提交的文件，Geode Capital Management LLC 拥有 Tonix Pharmaceuticals 约 105.45% 的股份，价值 650,000 美元。</p>
</div><p>Get <strong>Tonix Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tonix Pharmaceuticals</strong> 警报：</p>
</div><ul>
<li>Pharma Frenzy: Volatility Ignites Biotech Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>制药狂潮：波动性点燃生物技术行业</li>
</ul>
</div><p>Separately, Commonwealth Equity Services LLC bought a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth $40,000. 82.26% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>另外，Commonwealth Equity Services LLC 在第四季度购买了 Tonix Pharmaceuticals 的新股份，价值 40,000 美元。目前 82.26% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>TNXP has been the topic of a number of research reports. Noble Financial reiterated an &#34;outperform&#34; rating and issued a $70.00 price target on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th. StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a &#34;sell&#34; rating on the stock.</p>
<div class="lb-trans"><p>TNXP 一直是多份研究报告的主题。Noble Financial 在 3 月 20 日的报告中重申了 &#34;跑赢大盘&#34; 的评级，并对 Tonix Pharmaceuticals 的股票设定了 70.00 美元的目标价。StockNews.com 于 2 月 10 日的研究报告中开始覆盖 Tonix Pharmaceuticals，并对该股票给予了 &#34;卖出&#34; 的评级。</p>
</div><ul>
<li>Is Tonix Pharmaceuticals the Next Biotech Breakout?</li>
</ul>
<div class="lb-trans"><ul>
<li>Tonix Pharmaceuticals 是下一个生物技术突破吗？</li>
</ul>
</div><p><strong>View Our Latest Analysis on Tonix Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Tonix Pharmaceuticals 的最新分析</strong></p>
</div><h2>Tonix Pharmaceuticals Trading Up 10.9 %</h2>
<div class="lb-trans"><h2>Tonix Pharmaceuticals 股价上涨 10.9%</h2>
</div><p>Shares of TNXP opened at $20.00 on Monday. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $6.76 and a fifty-two week high of $672.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company's fifty day moving average is $16.88 and its 200 day moving average is $20.69. The stock has a market capitalization of $128.70 million, a PE ratio of 0.00 and a beta of 1.50.</p>
<div class="lb-trans"><p>周一，TNXP 的股价开盘为 20.00 美元。Tonix Pharmaceuticals Holding Corp. 的 52 周低点为 6.76 美元，52 周高点为 672.00 美元。该公司的债务与股本比率为 0.07，速动比率为 2.81，流动比率为 3.33。该公司的 50 日移动平均线为 16.88 美元，200 日移动平均线为 20.69 美元。该股票的市值为 1.287 亿美元，市盈率为 0.00，贝塔值为 1.50。</p>
</div><p>Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($9.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The business had revenue of $2.58 million for the quarter, compared to analysts' expectations of $3.20 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Tonix Pharmaceuticals（NASDAQ:TNXP - 获取免费报告）最后一次公布财报是在 3 月 18 日，报告显示该季度每股收益（EPS）为（9.77）美元，低于市场共识预期的（6.23）美元，差额为（3.54）美元。该季度的营业收入为 258 万美元，而分析师的预期为 320 万美元。Tonix Pharmaceuticals 的净利润率为负 1,197.86%，股本回报率为负 163.95%。卖方分析师预计 Tonix Pharmaceuticals Holding Corp. 在当前财政年度的每股收益将为 -1762.5。</p>
</div><h2>Tonix Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Tonix Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.</p>
<div class="lb-trans"><p>Tonix Pharmaceuticals Holding Corp. 是一家生物制药公司，专注于开发、发现、商业化和许可治疗人类疾病和减轻痛苦的治疗药物。它市场销售 Zembrace SymTouch 和 Tosymra，用于治疗成人急性偏头痛（有或没有先兆）。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Tonix Pharmaceuticals</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>Western Digital: Is the Storage Sector Set for a Rebound?</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Wingstop Stock Jumps on Q1 Beat, Expansion Outlook</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>Why Energy Stocks Like Exxon and Hess Are Back in Focus</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Tonix Pharmaceuticals</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>西部数据：存储行业是否准备反弹？</li>
<li>深入了解买卖差价</li>
<li>Wingstop 股票因第一季度业绩超预期和扩张前景而上涨</li>
<li>三只股票保护您的投资组合免受冠状病毒传播的影响</li>
<li>为什么像埃克森美孚和赫斯这样的能源股票重新受到关注</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5YUA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TNXP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tonix Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Tonix Pharmaceuticals 吗？</h2>
</div><p>Before you consider Tonix Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Tonix Pharmaceuticals 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Tonix Pharmaceuticals 并不在名单上。</p>
</div><p>While Tonix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tonix Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Geode Capital Management LLC 购买了 1,855,907 股 Tonix Pharma（NASDAQ:TNXP）的股票